Greater US FDA And Manufacturer Transparency Recommended As Key to Supply Chain Resilience
Executive Summary
Manufacturers could risk losing FDA product approvals if they fail to publicize sourcing and quality information, under new proposals. National Academies expert panel says supply chain transparency – not a pandemic-induced rush to onshoring requirements – provides the framework to mitigate against and respond to drug shortages.
You may also be interested in...
FDA Email Alert: Next Day’s Manufacturing Volume Reporting Due Date Still Voluntary
Objections to 15 February reporting date established in draft guidance spurred rare last-minute notice assuring industry that it was a non-binding recommendation, not a requirement. Action reflects confusion that can arise in interpreting policy guidance.
Consortium Costs Debated As BARDA, Industry Discuss Plans For Next Pandemic Response
BARDA’s consortium approach scrutinized as industry recovers from US Defense Production Act rated orders. Questions of sustainment fees, interruptible commercial activities explored during BioMaC Industry Day call as agency emphasizes need for proven capacity.
Generic Firms Want Congress To Build On CARES Act To Prevent Critical Drug Shortages
The association for manufacturers of generics and biologics calls for public sector investment in priority medicines.